Warm Acupuncture for Breast Cancer Related Lymphedema
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03373474|
Recruitment Status : Recruiting
First Posted : December 14, 2017
Last Update Posted : December 18, 2018
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer Lymphedema||Other: local distribution points association Other: local-distal points association||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||108 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Comparison of Effectiveness Between Warm Acupuncture With Local-Distal Points Association and Local Distribution Points Association in Breast Cancer Related Lymphedema Patients: A Multicenter, Randomized, Controlled Clinical Trial|
|Actual Study Start Date :||January 20, 2018|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||May 2019|
Experimental: local distribution points association
Participants will receive warm acupuncture with the local distribution acupoints association on the affected arm only.
Other: local distribution points association
Participants will receive acupuncture treatments using the local points set plus the local-addition points set (local distribution association) described below. Warming acupuncture will be applied at HT2, LI11, and TE9 if permitted.
Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Local-addition points set: LU5, PC3, SI7, TE4, TE3, HT2, TE10, LI15, and 2 other points according to the symptom on the affected arm.
Experimental: local-distal points association
Participants will receive warm acupuncture with the local-distal acupoints association on the affected arm, unaffected arm, abdomen, and legs.
Other: local-distal points association
Participants will receive acupuncture treatments using the local points set plus the distal points set (local-distal association) described below. Warming acupuncture will be applied similarly to the local distribution group, with the addition of Ren6, Ren9, bilateral SP9, and LI11 on the unaffected arm.
Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Distal points set: TE5, LI11, HT3, TE13 on the unaffected arm; CV4, CV6, CV9, CV12, bilateral SP6 and SP9.
No Intervention: waiting-list
Patients in the waiting-list group will not receive any acupuncture treatment during the study. However, for ethical consideration, 20 free acupuncture treatments will be offered after the study is completed.
- Upper extremity circumference [ Time Frame: 8 weeks ]Various assessment methods are available but circumference measure is simple, convenient with low cost, and reliable. Therefore, the primary outcome measures will be the mean change in inter-limb circumference difference from baseline to the end of the 8-week intervention. The circumference will be measured by the measurement tape (Gulick Attachment, Baseline, America) at the wrist crease, 10 cm above the wrist crease, elbow crease, 10 cm above the elbow crease, where the lymphedema is most severe and its corresponding location on the unaffected limb.
- Upper extremity volume [ Time Frame: 8 weeks ]Volume measurement is also commonly used for the evaluation of lymphedema and the mean change in inter-limb volume difference from baseline to the end of the 8-week intervention will be included as the second primary outcome measure. The volume of the affected and unaffected limb will be measured by the volumetric measuring device (Baseline, America) using the water displacement method, which is considered as the most reliable method for volume measurements.
- Skin hardness [ Time Frame: 8 weeks ]Skin hardness will be measured at places where the skin feels most tense to the touch by the NEUTONE TDM-NA1 (DX) muscle hardness tester (Try-All Corporation, Chiba City, Japan). The location of the measurement will be recorded and the corresponding location on the unaffected limb will also be measured to obtain inter-limb difference in skin hardness.
- Common terminology criteria for adverse events (CTCAE 4.03) - edema limbs criteria [ Time Frame: 8 weeks ]Common terminology criteria for adverse events (CTCAE 4.03) will be used to grade the severity of swelling using the edema limbs criteria. A grading of mild, moderate or severe swelling will be assessed based on the inter-limb circumference or volume discrepancy, anatomic architecture, appearance, or activities of daily living. The CTCAE 4.03 will allow us to evaluate the clinical significance of circumference change.
- Stages of lymphedema from the international society of lymphology [ Time Frame: 8 weeks ]Stages of lymphedema from the international society of lymphology will be used to grade the severity of lymphedema. Staging of 0, I, II, or III will be assessed based on severity of swelling, ability to reduce swelling by elevation, and skin changes.
- The Disabilities of the Arm, Shoulder and Hand (DASH) Outcome Measure [ Time Frame: 8 weeks ]Disabilities of the arm, shoulder, and hand (DASH) is a scale consists of two concepts: functional status (part A) and symptoms (part B) respectively. The functional status part is further divided into three dimensions: physical, social, and psychological. The total score of the DASH ranges from 0 to 100 with higher scores representing worse symptoms and function. The DASH has good validity and responsiveness and it is recommended to assess upper extremity function in breast cancer survivors. The validated Chinese version of the DASH will be used in this study.
- The MOS 36-Item Short-Form Health Survey (SF-36) [ Time Frame: 8 weeks ]The medical outcome study 36-item short-form health survey (SF-36) is a commonly used instrument to assess quality of life that has good validity. The SF-36 includes the following eight concepts: physical functioning, role limitations due to physical problems, social functioning, bodily pain, general mental health, role limitations due to emotional problems, vitality, and general health perception. The validated Chinese version of the SF-36 will be used in this study.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03373474
|Contact: XingFang Panfirstname.lastname@example.org|
|Baokang Hospital Affiliated to Tianjin University of Traditional Chinese Medicine||Recruiting|
|Tianjin, Tianjin, China|
|Contact: XingFang Pan 18649067519 email@example.com|
|Principal Investigator:||XingFang Pan||Baokang Hospital Affiliated to Tianjin University of Traditional Chinese Medicine|